Vasopressin Market, by Type (Intravenous Injection, Intramuscular Injection, and Subcutaneous Injection), by Application, (Anti-Diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock and Ventricular Tachycardia & Fibrillation), by End

Vasopressin Market, by Type (Intravenous Injection, Intramuscular Injection, and Subcutaneous Injection), by Application, (Anti-Diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock and Ventricular Tachycardia & Fibrillation), by End User (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Vasopressin is a nonapeptide produced in the hypothalamus, exhibits diverse physiological functions related to hemodynamic modulation, diuresis, and behavior. Vasopressin is similar to oxytocin, differing in the third and eight amino acid.
Vasopressin is indicated for the treatment of postoperative abdominal distention, abdominal roentgenography, Gastrointestinal Bleeding and diabetes insipidus.
Market Dynamics
The increasing approvals of vasopressin drug by regulatory authorities is expected to drive the global vasopressin market growth. For instance, in 2018, Eagle Pharmaceuticals, Inc., received abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration for its vasopressin injection, 1ml. Vasostrict had around US$ 400 million in brand sales in 2017, according to the Eagle Pharmaceuticals, Inc., company financial review.
Key features of the study:
This report provides in-depth analysis of the global vasopressin market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global vasopressin market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global vasopressin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vasopressin market
Detailed Segmentation:
Global Vasopressin Market, By Type:
Intravenous Injection
Intramuscular Injection
Subcutaneous Injection
Global Vasopressin Market, By Application:
Anti-Diuretic Hormone Deficiency
Gastrointestinal Bleeding
Vasodilatory Shock
Ventricular Tachycardia & Fibrillation
Global Vasopressin Market, By End User:
Hospital
Clinics
Others
Global Vasopressin Market, By Region:
North America
By Type
Intravenous Injection
Intramuscular Injection
Subcutaneous Injection
By Application
Anti-Diuretic Hormone Deficiency
Gastrointestinal Bleeding
Vasodilatory Shock
Ventricular Tachycardia & Fibrillation
By End User
Hospital
Clinics
Others
By Country
U.S.
Canada
Latin America
By Type
Intravenous Injection
Intramuscular Injection
Subcutaneous Injection
By Application
Anti-Diuretic Hormone Deficiency
Gastrointestinal Bleeding
Vasodilatory Shock
Ventricular Tachycardia & Fibrillation
By End User
Hospital
Clinics
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type
Intravenous Injection
Intramuscular Injection
Subcutaneous Injection
By Application
Anti-Diuretic Hormone Deficiency
Gastrointestinal Bleeding
Vasodilatory Shock
Ventricular Tachycardia & Fibrillation
By End User
Hospital
Clinics
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Type
Intravenous Injection
Intramuscular Injection
Subcutaneous Injection
By Application
Anti-Diuretic Hormone Deficiency
Gastrointestinal Bleeding
Vasodilatory Shock
Ventricular Tachycardia & Fibrillation
By End User
Hospital
Clinics
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type
Intravenous Injection
Intramuscular Injection
Subcutaneous Injection
By Application
Anti-Diuretic Hormone Deficiency
Gastrointestinal Bleeding
Vasodilatory Shock
Ventricular Tachycardia & Fibrillation
By End User
Hospital
Clinics
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Type
Intravenous Injection
Intramuscular Injection
Subcutaneous Injection
By Application
Anti-Diuretic Hormone Deficiency
Gastrointestinal Bleeding
Vasodilatory Shock
Ventricular Tachycardia & Fibrillation
By End User
Hospital
Clinics
Others
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Par Pharmaceutical*
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Pfizer Inc.
Novartis AG
Ferring Pharmaceuticals
Fresenius Kabi Canada
Astellas Pharma
Shanghai Soho-Yiming Pharmaceuticals
Endo International
Hybio Pharmaceutical
Hainan Zhonghe Pharmaceutical
Cumberland Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.